The disease causes inflammation of the
gastrointestinal tract, typically resulting in symptoms such as diarrhea,
fever , abdominal pain and weight loss. It is estimated that 500,000
Americans and more than 400,000 people in Europe and Canada suffer from
this gastrointestinal disorder.

organism proteins

g.gov.
Riff, MD, Medical Director , Advanced Clinical Research Institute, Anaheim,
California. Centocor's products, developed primarily
through monoclonal antibody technology, help physicians deliver innovative
treatments to improve human health and restore patients' quality of life.

vidhu organism

However, unlike influenza, the disease may
progress rapidly and within hours of symptoms onset, may cause permanent
disability or death. announced today the
extension of patient enrollment for a Phase II trial to evaluate the safety
and efficacy of CNTO 1275 for reducing the signs and symptoms of active
Crohn's disease (CD), a serious gastrointestinal disorder.

incidence bacterium

The committee
indicated that recommendations may be expanded to include additional
adolescent age groups as vaccine supply increases in the coming years. Symptoms include high fever,
headache , stiff neck, confusion, nausea, vomiting, exhaustion, and a rash may
appear. CNTO 1275 is a
human monoclonal antibody that targets interleukin 12 (IL-12) and
interleukin 23 (IL-23), proteins that occur naturally in the immune system
and are believed to play a role in the inflammation associated with CD.

proteins epidemics

Although rare,
meningococcal disease is dangerous, because early symptoms resemble influenza ,
making it difficult to recognize.

PRESS RELEASE Centocor Extends Patient Enrollment to Evaluate CNTO 1275 in Treatment of Active Crohn's Disease

"

Patients who are eligible to participate in the 28-week study will be
randomized at week 0 to one of four treatment groups to receive active drug
or placebo. Patients will be monitored through 28 weeks with an
additional visit at week 54 for a final blood test.

epidemics infectious

Clarification of the Newly Approved Meningococcal Disease Vaccination Recommendations of the Advisory Committee on Immunization Practices

, This media alert by the National
Foundation for Infectious Diseases (NFID) has been issued due to various news
reports that did not fully specify each of the age groups for which the new
meningococcal immunization recommendations were approved by the Advisory
Committee on Immunization Practices (ACIP).org or CDC's Web site at
http://www .

Founded in 1973, NFID is a non-profit organization dedicated to public and
professional educational programs about infectious diseases.

medlineplus thaker

emedicine cholera

nobel organism

Meningococcal disease is the most common cause of bacterial meningitis in
U.S.

Cholera is caused by an enterotoxin produced by the bacterium Vibrio cholerae.

proteins epidemics

medlineplus bacterium

Lifestyle factors thought to contribute to the disease include direct
contact with infected persons, e.

emedicine epidemics

epidemics nobel

, exchanging saliva, often through kissing;
crowded living conditions, e.

handa bacterium

Subjects will be permitted to remain on certain standard CD
medications, including steroids and immunomodulators , while participating
in the study.D.

epidemic infectious

, dormitories; and active or passive smoking.

Contact: Jennifer Corrigan 732-382-8898
Heather Carman 212-886-2200

For more information about clinical trial sites and specific study
protocol, please call 1-800-624-7994 .
Centocor is a wholly owned subsidiary of Johnson & Johnson, the worldwide
manufacturer of healthcare products.

bacterium incidence

BETHESDA, Md. toddlers, adolescents and young adults.

About Centocor

Centocor is a leading biopharmaceutical company that creates, acquires and
markets cost-effective therapies that yield long-term benefits for patients
and the healthcare community.

factsheets organism

Health experts approved these recommendations in response to disease
epidemiology data showing an increased risk for disease among adolescents and
young adults, and the availability of a new meningococcal conjugate vaccine
expected to provide longer term protection from the disease.
For more information about meningococcal meningitis vaccination, visit the
NFID's Web site at http://www. The company is dedicated to the research and
development of treatments for a wide range of diseases including cancer,
infectious diseases, cardiovascular and metabolic diseases and
Immune-Mediated Inflammatory Disorders (I.

medlineplus bacterium

), such as arthritis and
inflammatory skin diseases.

There have been and continue to be massive pandemics of this disease across the world.

cholera bacterium

g.

"This study will evaluate the effect of a targeted, human anti-IL-12
monoclonal antibody on Crohn's disease and its symptoms," said Dennis S. "We look forward to further analysis and evaluation of this
therapy as a potential treatment for patients with moderate to severe
Crohn's disease.M.

medmicro bao

Centocor, Inc.

epidemic sajeev

I.

bao organisms

Vaccination is the best means of preventing meningococcal disease.cdc.

About Crohn's Disease

CD is a chronic inflammatory bowel disorder that commonly affects the lower
part of the small intestine and the large intestine and typically begins in
late childhood or early adulthood.

factsheets bacterial

By issuing this alert, NFID
encourages media reports to include a more complete listing/clarification of
the actual meningococcal disease immunization recommendations, which
specifically target the following age groups:

* Young adolescents at the adolescent visit (11-12 years old)
* Adolescents at high school entry (15 years old)
* College freshmen living in dormitories

ACIP approved the new recommendations to help ensure younger adolescents,
as well as college freshmen living in dormitories, are immunized against
meningococcal disease, commonly known as meningococcal meningitis or
meningococcemia, a potentially fatal bacterial infection.nfid.

infectious bacterium

incidence cholera

epidemics vidhu

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)